Rayos articles & resources on Made-in-China.com

Horizon Pharma and SkyePharma Have Filed a Patent Infringement Lawsuit

Aug 30, 2013

Horizon Pharma and SkyePharma have filed a patent infringement lawsuit against Watson Laboratories (WLF) and certain related companies like Actavis Pharma, Andrx and Actavis Inc. The lawsuit was filed in the US District Court for the ...

Tags: Horizon Pharma

Horizon Pharma Has Commenced The Full Commercial Launch of Rayos Delayed-Release Tablets

Feb 18, 2013

Specialty pharmaceutical company Horizon Pharma has commenced the full commercial launch of Rayos (Prednisone) delayed-release tablets for rheumatology indications, such as rheumatoid arthritis and polymyalgia rheumatica. Rayos is a ...

Tags: Horizon Pharma, Rayos, delayed-release tablets, rheumatology indications

Pharma Announced The Issuance of Additional Notice of Allowance From The US Patent

Feb 13, 2013

Horizon Pharma has announced the issuance of additional notice of allowance from the US Patent and Trademark Office for Rayos (Prednisone) delayed-release tablets. Skyepharma received the notice of allowance for US patent application ...

Tags: Horizon Pharma, Rayos, release tablets

Horizon Pharma Has Commercially Launched Rayos Delayed Release Tablets in The US

Dec 10, 2012

Horizon Pharma has commercially launched Rayos (prednisone) delayed release tablets in the US. Rayos is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma ...

Tags: Horizon Pharma, Rayos, rheumatoid arthritis

Horizon Pharma RAYOS Tabletsreceived FDA Approval

Dec 7, 2012

Horizon Pharma RAYOS (prednisone) delayed-release tablets have received the US Food and Drug Administration (FDA) approval. The approved drug is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis ...

Tags: Horizon Pharma RAYOS delayed-release tablets, rheumatoid arthritis, RA

USPTO Granted NOA to SkyePharma for a Patent Application 2012/0177734

Dec 5, 2012

The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...

Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis